$264.48
4.211.62%
At close: Jun 12, 5:00 PM EST
$264.48
N/A
After Hours: 4:00 PM EST
BeOne Medicines Ltd Stock Guidance
ONCNASDAQ
BeOne Medicines (ONC) last issued guidance on May 6, 2026 for fiscal year 2026. The company guided revenue in the range of $6.30B - $6.50B for the period.
Compared to prior guidance, BeOne Medicines raised its revenue forecast from a prior range of $6.20B - $6.40B.
BeOne Medicines has issued 6 guidance updates between February 27, 2025 and May 6, 2026. During this period, the company raised its outlook 2 times, reflecting management's growing confidence in business performance.
Latest Guidance Date
May 6, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$6.30B - $6.50B
BeOne Medicines Guidance History
Review all historical guidance issued by BeOne Medicines, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for BeOne Medicines (ONC)?
The most recent guidance for BeOne Medicines (ONC) was reported on May 6, 2026 for the fiscal year 2026. BeOne Medicines forecasted revenue between $6.30B and $6.50B for the period.
What revenue range did BeOne Medicines (ONC) guide for?
BeOne Medicines (ONC) guided revenue in the range of $6.30B to $6.50B for the fiscal year 2026.
Did BeOne Medicines (ONC) raise or lower guidance?
BeOne Medicines (ONC) raised its revenue guidance from a prior range of $6.20B - $6.40B to $6.30B - $6.50B for the fiscal year 2026.
When did BeOne Medicines (ONC) last issue guidance?
BeOne Medicines (ONC) last issued guidance on May 6, 2026 for the fiscal year 2026.
